Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 679
- Registration Number
- NCT03879772
Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 621
- Registration Number
- NCT03867318
An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 628
- Registration Number
- NCT03867110
Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT03861559
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 704
- Registration Number
- NCT03855228
Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 345
- Registration Number
- NCT03855189
Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 454
- Registration Number
- NCT03768427
- Locations
- 🇨🇳
Central People s Hospital of Siping ( Site 0046), Siping, Jilin, China
🇨🇳The First Affiliated Hospital of Baotou Medical College ( Site 0025), Baotou, Anhui, China
🇨🇳Chongqing General Hospital ( Site 0037), Chongqing, Chongqing, China
Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 17
- Registration Number
- NCT03019575
- Locations
- 🇧🇷
Hosp das Clinicas da Faculdade de Medicina da Univ de Sao Paulo ( Site 0015), Sao Paulo, Brazil
🇲🇽Hospital Infantil de Mexico Federico Gomez ( Site 0006), Mexico City, Mexico
🇷🇺City children polyclinic #44 ( Site 0025), Saint Petersburg, Russian Federation
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 135
- Registration Number
- NCT02748057
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 181
- Registration Number
- NCT02741271
© Copyright 2024. All Rights Reserved by MedPath